Metraipolis › archive › dc_37deb61eae34

Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41037103
DOI
10.1007/s00277-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-11-10T04:52:40.222Z
SHA-256 of the archived text
6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d
Stable URL of this page
https://metraipolis.com/documento/dc_37deb61eae34

How to cite

Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103 — Europe PMC (en), https://europepmc.org/article/MED/41037103 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37deb61eae34 (Metraipolis archive dc_37deb61eae34, sha256 6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d)
BibTeX
@misc{dc37deb61eae34,
  title = {Lenalidomide-rituximab with high-dose methotrexate for treatment of patients with newly diagnosed primary cns lymphoma: a promising first-line approach — Europe PMC PMID:41037103},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41037103},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37deb61eae34; sha256 6b0ab4731e66a1c71c42bea69a6586b5c889e34b0f9d804ba0359d5ff550c16d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41037103. Agents can read the archived copy with the MCP tool read_document.